Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Markus Hansson
Institutions:
Sahlgrenska University Hospital,
Region Västra Götaland,
Skåne University Hospital,
University of Gothenburg
Observed institutions:
Sahlgrenska University Hospital,
Region Västra Götaland,
Skåne University Hospital,
University of Gothenburg
ORCID:
0000-0002-7715-4548
Observed ORCID:
0000-0002-7715-4548
OpenAlex ID:
A5099591435
Adjuvant histamine in cancer immunotherapy
2000
·
Kristoffer Hellstrand
, Markus Hansson
, et al.
·
Seminars in Cancer Biology
·
23
Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study
2026
·
Noffar Bar
, Thomas Martin
, et al.
·
Leukemia
·
13
PDF
Myeloid‐Derived Suppressor Cells (MDSCs) Suppress T‐Cell Proliferation Less Than Mature Neutrophils in Blood and Bone Marrow From Multiple Myeloma Patients
2026
·
Julia Westerlund
, Sandra Askman
, et al.
·
Journal of Immunology Research
·
5
PDF
Respiratory syncytial virus and other vaccine-preventable infections in multiple myeloma. A population-based study on 8,672 myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry
2024
·
Sigrun Einarsdottir
, Ingigerdur Sverrisdottir
, et al.
·
Haematologica
·
4
PDF
Human papillomavirus vaccination (HPV) in immunocompromised adults: Rationale, evidence, and clinical guidance
2026
·
Cecilia Olofsson
, Markus Hansson
, et al.
·
Vaccine X
·
2
Safety results from REALiTAL: A multi-country observational retrospective study of talquetamab in patients with relapsed/refractory multiple myeloma outside of clinical trials
2025
·
Rakesh Popat
, Katarina Uttervall
, et al.
·
Blood
·
1
PDF
Show more works
View as search
Works count:
6
Citation count:
48
H-index:
4
I10-index:
2
Year
Topic
Type